Form 4: DexCom Director Mark Foletta Receives RSU Grant

DexCom, Inc. director Mark G. Foletta was granted 6,331 restricted stock units as part of standard equity compensation.

Summary

• Director Mark G. Foletta received an award of 6,331 restricted stock units (RSUs) on May 28, 2026.
• The RSUs represent a contingent right to receive one share of DexCom common stock per unit upon settlement.
• The award is scheduled to vest fully on the earlier of the one-year anniversary of the grant date or the 2027 Annual Meeting of Stockholders.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral, routine administrative filing regarding director compensation.

Positives

• Equity-based compensation aligns director interests with long-term shareholder value.

Negatives

• None identified; this is a routine compensatory filing.

Risks

• None identified; this is a routine compensatory filing.

Future Outlook

The RSU award is expected to vest in full by the 2027 Annual Meeting of Stockholders or the one-year anniversary of the grant.

Industry Context

StockSavvy.ai notes that routine equity grants to board members are standard corporate governance practices in the medical technology sector to ensure director retention and alignment with company performance.

Comparison to Industry Standards

• The grant of RSUs to non-employee directors is consistent with standard compensation practices for S&P 500 and mid-cap healthcare companies.

Related Party Transactions

• The reporting person holds 56,852 shares indirectly through The Foletta Family Trust.

Stakeholder Impact

• Minimal impact; represents standard director equity compensation.

Next Steps

• Vesting of the RSU award on the earlier of May 28, 2027, or the 2027 Annual Meeting of Stockholders.

Key Dates

Keywords

DexCom, DXCM, Form 4, Insider Trading, Equity Compensation, Director Compensation